The newest agents
The 2023–2026 approvals and frontier agents in the atlas, profiled and grounded in PubMed. A weekly discovery pass scans the literature for new nephrotoxicity signals.
2026
7 agentsGedatolisib
Pan-PI3K inhibitor
Iberdomide
Cereblon E3 ligase modulator (CELMoD)
Pivekimab sunirine
CD123 antibody-drug conjugate
Relacorilant
Selective glucocorticoid-receptor antagonist
Sonrotoclax
BCL-2 inhibitor
Vepdegestrant
PROTAC estrogen-receptor degrader
Zidesamtinib
ROS1-selective TKI
2025
14 agentsAvutometinib
RAF/MEK inhibitor
Datopotamab deruxtecan (Dato-DXd)
Antibody-drug conjugate (TROP2/DXd)
Dordaviprone
Imipridone (ONC201; DRD2/ClpP)
Imlunestrant
Oral selective estrogen-receptor degrader (SERD)
Linvoseltamab
BCMA×CD3 bispecific T-cell engager
Mirdametinib
MEK inhibitor
Penpulimab
PD-1 immune checkpoint inhibitor
Sevabertinib
HER2/EGFR TKI
Sunvozertinib
EGFR exon20 TKI
Taletrectinib
ROS1 TKI
Telisotuzumab vedotin (Teliso-V)
c-Met ADC (MMAE)
Vimseltinib
CSF1R tyrosine kinase inhibitor
Ziftomenib
Menin inhibitor
Zongertinib
HER2 TKI
2024
19 agentsAfamitresgene autoleucel (Afami-cel)
MAGE-A4 TCR-T cell therapy
Cosibelimab
PD-L1 immune checkpoint inhibitor
Denileukin diftitox
Immunotoxin (IL-2–diphtheria)
Ensartinib
ALK TKI
Imetelstat
Telomerase inhibitor
Inavolisib
PI3Kα inhibitor
Ivonescimab
PD-1 x VEGF bispecific antibody
Lazertinib
EGFR TKI (3rd-gen)
Lifileucel
Tumor-infiltrating lymphocyte (TIL) therapy
Obecabtagene autoleucel (Obe-cel)
CD19 CAR-T cell therapy
Odronextamab
Bispecific (CD20×CD3)
Revumenib
Menin inhibitor
Tarlatamab
Bispecific T-cell engager (DLL3-directed BiTE)
Tislelizumab
PD-1 immune checkpoint inhibitor
Tovorafenib
Type II pan-RAF (BRAF) inhibitor
Vorasidenib
Mutant IDH1/2 inhibitor
Zanidatamab
HER2 bispecific antibody
Zenocutuzumab
HER2×HER3 bispecific antibody
Zolbetuximab
Anti-Claudin-18.2 monoclonal antibody
2023
10 agentsCapivasertib
AKT inhibitor
Elacestrant
Oral selective estrogen-receptor degrader (SERD)
Fruquintinib
VEGFR TKI
Momelotinib
JAK/ACVR1 inhibitor
Nirogacestat
Gamma-secretase inhibitor
Pirtobrutinib
Non-covalent BTK inhibitor
Quizartinib
FLT3 inhibitor
Repotrectinib
ROS1/TRK TKI
Retifanlimab
PD-1 immune checkpoint inhibitor
Toripalimab
PD-1 immune checkpoint inhibitor
Newest approvals shown; the full era breakdown lives on the atlas.